GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Cash Flow from Others

BCAX (Bicara Therapeutics) Cash Flow from Others : $-0.21 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Cash Flow from Others?

Bicara Therapeutics's cash flow from others for the three months ended in Dec. 2024 was $-0.28 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.21 Mil.


Bicara Therapeutics Cash Flow from Others Historical Data

The historical data trend for Bicara Therapeutics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Cash Flow from Others Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Cash Flow from Others
- 13.50 -0.08

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Jun24 Sep24 Dec24
Cash Flow from Others Get a 7-Day Free Trial 13.35 0.68 - 0.07 -0.28

Bicara Therapeutics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.21 Mil.

Bicara Therapeutics Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Bicara Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.